Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population

[1]  Shinichi Sato,et al.  Serum levels of interleukin‐18‐binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis , 2016, The Journal of dermatology.

[2]  P. Nilsson,et al.  Implementation of World Health Organization Package of Essential Noncommunicable Disease Interventions (WHO PEN) for Primary Health Care in Low‐Resource Settings: A Policy Statement From the World Hypertension League , 2016, Journal of clinical hypertension.

[3]  S. Koca,et al.  The IL-33 gene is related to increased susceptibility to systemic sclerosis , 2016, Rheumatology International.

[4]  G. Efimov,et al.  Modern anti-cytokine therapy of autoimmune diseases , 2014, Biochemistry (Moscow).

[5]  E. Hsieh,et al.  Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China. , 2014, Clinical and experimental rheumatology.

[6]  E. Feskens,et al.  Combined Effects of Smoking and Alcohol on Metabolic Syndrome: The LifeLines Cohort Study , 2014, PloS one.

[7]  G. Valentini,et al.  Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels , 2014, Journal of Clinical Immunology.

[8]  M. Sospedra,et al.  Boswellic acids reduce Th17 differentiation via blockade of IL‐1β‐mediated IRAK1 signaling , 2014, European journal of immunology.

[9]  Ho‐Youn Kim,et al.  Increased Th17 differentiation in aged mice is significantly associated with high IL-1β level and low IL-2 expression , 2014, Experimental Gerontology.

[10]  C. Garlanda,et al.  The interleukin-1 family: back to the future. , 2013, Immunity.

[11]  S. Sedimbi,et al.  IL-18 in inflammatory and autoimmune disease , 2013, Cellular and Molecular Life Sciences.

[12]  J. Laar,et al.  Update on Stem Cell Transplantation for Systemic Sclerosis: Recent Trial Results , 2013, Current Rheumatology Reports.

[13]  M. Ohtsuki,et al.  Serum levels of interleukin‐1α in patients with systemic sclerosis , 2013, The Journal of dermatology.

[14]  T. Gambichler,et al.  Increased serum IL-33 levels may indicate vascular involvement in systemic sclerosis , 2012, Annals of the rheumatic diseases.

[15]  D. Ye,et al.  Association of interleukin-18 and systemic lupus erythematosus , 2013, Rheumatology International.

[16]  C. Artlett.  The Role of the NLRP3 Inflammasome in Fibrosis , 2012, The open rheumatology journal.

[17]  D. Ye,et al.  Interleukin-18: friend or foe for systemic sclerosis? , 2011, The Journal of investigative dermatology.

[18]  C. Feghali-Bostwick,et al.  The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. , 2011, Arthritis and rheumatism.

[19]  A. Koch,et al.  Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[20]  T. Sandström,et al.  Cytokine mRNA Profile of Alveolar T Lymphocytes and Macrophages in Patients with Systemic Sclerosis Suggests a Local Tr1 Response , 2011, Scandinavian journal of immunology.

[21]  M. Conforti,et al.  Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement , 2011, Annals of the rheumatic diseases.

[22]  K. Yanaba,et al.  Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis , 2011, Clinical Rheumatology.

[23]  D. Abraham,et al.  Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. , 2010, The Journal of investigative dermatology.

[24]  D. Cho,et al.  IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway. , 2010, The Journal of investigative dermatology.

[25]  Sun Ming-j.  The Effect of Long-term Alcohol Intake on Circadian Rhythm of Ambulatory Blood Pressure in Males with Hypertension , 2010 .

[26]  I. McInnes,et al.  IL‐33 is a chemoattractant for human Th2 cells , 2007, European journal of immunology.

[27]  David Abraham,et al.  Systemic sclerosis: a prototypic multisystem fibrotic disorder. , 2007, The Journal of clinical investigation.

[28]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[29]  E. Hofny,et al.  Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1β, and tumour necrosis factor α in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis , 2005, Journal of Clinical Pathology.

[30]  Simon C Watkins,et al.  Autocrine activation by interleukin 1alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. , 2004, The Journal of rheumatology.

[31]  T. Wright,et al.  A nuclear target for interleukin-1α: Interaction with the growth suppressor necdin modulates proliferation and collagen expression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. El-Deek,et al.  Proinflammatory cytokines (IL-12 and IL-18) in immune rheumatic diseases: relation with disease activity and autoantibodies production. , 2003, The Egyptian journal of immunology.

[33]  T. Wright,et al.  Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A , 1999 .

[34]  T. Wright,et al.  Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. , 1999, The Journal of clinical investigation.

[35]  M. Harigai,et al.  Interleukin 1 Receptor on Fibroblasts from Systemic Sclerosis Patients Induces Excessive Functional Responses to Interleukin 1β , 1993 .

[36]  M. Harigai,et al.  Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1 beta. , 1993, Biochemical and biophysical research communications.

[37]  F. Wigley,et al.  Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. , 1992, Arthritis and rheumatism.

[38]  M. Murakami,et al.  Enhanced production of interleukin-1 and tumor necrosis factor alpha by cultured peripheral blood monocytes from patients with scleroderma. , 1990, Arthritis and rheumatism.

[39]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[40]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.